Jafron Biomedical Co Ltd
SZSE:300529
| US |
|
Microsoft Corp
NASDAQ:MSFT
|
Technology
|
| FR |
|
L'Air Liquide Societe Anonyme pour l'Etude et l'Exploitation des Procedes Georges Claude SA
PAR:AI
|
Chemicals
|
| FR |
|
LVMH Moet Hennessy Louis Vuitton SE
PAR:MC
|
Textiles, Apparel & Luxury Goods
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.6
37.82
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Microsoft Corp
NASDAQ:MSFT
|
US |
|
|
L'Air Liquide Societe Anonyme pour l'Etude et l'Exploitation des Procedes Georges Claude SA
PAR:AI
|
FR |
|
|
LVMH Moet Hennessy Louis Vuitton SE
PAR:MC
|
FR |
This alert will be permanently deleted.
Jafron Biomedical Co Ltd
Accounts Payable
Jafron Biomedical Co Ltd
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
J
|
Jafron Biomedical Co Ltd
SZSE:300529
|
Accounts Payable
¥133.1m
|
CAGR 3-Years
42%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
A
|
APT Medical Inc
SSE:688617
|
Accounts Payable
¥42.7m
|
CAGR 3-Years
72%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Accounts Payable
¥1.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
23%
|
CAGR 10-Years
17%
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Accounts Payable
¥3.9B
|
CAGR 3-Years
31%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
L
|
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
|
Accounts Payable
¥615m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
22%
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Accounts Payable
¥1.6B
|
CAGR 3-Years
23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Jafron Biomedical Co Ltd
Glance View
Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. The company is headquartered in Zhuhai, Guangdong and currently employs 2,887 full-time employees. The company went IPO on 2016-08-02. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.
See Also
What is Jafron Biomedical Co Ltd's Accounts Payable?
Accounts Payable
133.1m
CNY
Based on the financial report for Jun 30, 2024, Jafron Biomedical Co Ltd's Accounts Payable amounts to 133.1m CNY.
What is Jafron Biomedical Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
31%
Over the last year, the Accounts Payable growth was 93%. The average annual Accounts Payable growth rates for Jafron Biomedical Co Ltd have been 42% over the past three years , 31% over the past five years .
You don't have any saved screeners yet
